ARK THERAPEUTICS
DEAD

Serial Number

77937687

Owner

Ark Therapeutics Limited

Attorney

LEIGH ANN LINDQUIST

Filing Date

Feb 17, 2010

Add to watchlist:

No watchlists yet
View on USPTO

ARK THERAPEUTICS Trademark

Serial Number: 77937687 • Registration: 4184675

ARK THERAPEUTICS is a trademark filed by Ark Therapeutics Limited on February 17, 2010. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

Ark Therapeutics Limited (15 trademarks)

79 New Cavendish Street
London W1W 6XB , GB

Entity Type: 03

Trademark Details

Filing Date

February 17, 2010

Registration Date

August 7, 2012

Published for Opposition

April 3, 2012

Cancellation Date

March 8, 2019

Goods & Services

Diagnostic protein preparations for medical use; diagnostic preparations of genes for medical use; pharmaceutical preparations for the treatment of wounds, burns, vascular and circulatory system related diseases, cancer, malignant glioma and other malignant brain tumors, macular degeneration, lipodystrophy and other metabolic conditions associated with the use of anti-HIV therapy, cachexia and muscle wasting; pharmaceutical preparations for the prevention of stenosis, namely, stenosis caused by intimal hyperplasia following surgical procedures; pharmaceutical preparations to promote or suppress angiogenesis and enhance blood flow; pharmaceutical preparations for increasing the efficiency of muscle cell energy production; therapeutic agents for the treatment of wounds, burns, vascular and circulatory system related diseases, cancer, malignant glioma and other malignant brain tumors, macular degeneration, lipodystrophy and other metabolic conditions associated with the use of anti-HIV therapy, cachexia and muscle wasting; therapeutic agents for the prevention of stenosis, namely, stenosis caused by intimal hyperplasia following surgical procedures; therapeutic agents to promote or suppress angiogenesis and enhance blood flow; therapeutic agents for increasing the efficiency of muscle cell energy production; diagnostic preparations for medical purposes; protein preparations for clinical or medical laboratory use, namely, for targeting therapeutic agents to specific sites; medical dressings; surgical dressings; burn dressings; wound dressings; absorbent wound and burn dressings in the nature of pads; foot and hand dressings for medical purposes; fluid handling foot and hand dressings for medical purposes; preparations of genes for therapeutic purposes, namely, for the treatment of wounds, burns, vascular and circulatory system related diseases, cancer, malignant glioma and other malignant brain tumors, macular degeneration, lipodystrophy and other metabolic conditions associated with the use of anti-HIV therapy, cachexia and muscle wasting; preparations of genes for therapeutic purposes, namely, for the prevention of stenosis, namely, stenosis caused by intimal hyperplasia following surgical procedures; preparations of genes for therapeutic purposes, namely, to promote or suppress angiogenesis and enhance blood flow; preparations of genes for therapeutic purposes, namely, for increasing the efficiency of muscle cell energy production; foot and hand dressings for medical purposes, namely, for the treatment of wounds and burns; none of the above including dietary and nutritional supplements

Diagnostic protein preparations for use in science, scientific diagnostics, medical laboratory use and research; diagnostic preparations of genes for use in science, scientific diagnostics, medical laboratory use and research

Boots and gloves for orthopaedic and medical purposes; parts of boots and gloves for orthopedic and medical purposes, namely, heels, soles and inserts; boots and gloves for medical purposes with the ability to handle wound fluid; boots and gloves for medical use and absorbent filters, liners and inserts for use therewith; filters, soles and absorbent inserts for boots and gloves for medical purposes, namely, for the treatment of wounds and burns; biodegradable collagen collar delivery devices for delivering therapeutic agents and gene therapy products to specific sites

Scientific, medical and clinical research, all in the field of the treatment of wounds, burns, vascular and circulatory system related diseases, cancer, malignant glioma and other malignant brain tumors, macular degeneration, lipodystrophy and other metabolic conditions associated with the use of anti-HIV therapy, cachexia and muscle wasting, prevention of stenosis, increasing the efficiency of muscle cell energy production and promoting or suppressing angiogenesis and enhancing blood flow; providing scientific, medical and clinical research information, all in the field of the treatment of wounds, burns, vascular and circulatory system related diseases, cancer, malignant glioma and other malignant brain tumors, macular degeneration, lipodystrophy and other metabolic conditions associated with the use of anti-HIV therapy, cachexia and muscle wasting, prevention of stenosis, increasing the efficiency of muscle cell energy production and promoting or suppressing angiogenesis and enhancing blood flow; scientific, medical and clinical research for the discovery, design, creation, development and testing in the field of pharmaceutical preparations and therapeutically active substances; scientific, medical and clinical research in the field of gene therapy; scientific, medical and clinical research for the discovery, design, creation, development and testing in the field of pharmaceutical preparations and therapeutically active substances for use in the field of gene therapy; scientific, medical and clinical research in the field of genes and genetics; medical and scientific research, namely, conducting gene therapy trials; none of the above in the dietary or nutritional supplement field

Filing History

CANCELLED SEC. 8 (6-YR)
Mar 8, 2019 C8..
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Aug 7, 2017 REM1
REGISTERED-PRINCIPAL REGISTER
Aug 7, 2012 R.PR
1(B) BASIS DELETED; PROCEED TO REGISTRATION
Jun 28, 2012 DP1B
NOTICE OF ALLOWANCE CANCELLED
Jun 28, 2012 IUCN
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Jun 28, 2012 AITU
TEAS DELETE 1(B) BASIS RECEIVED
Jun 22, 2012 D1BR
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
May 29, 2012 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 3, 2012 NPUB
PUBLISHED FOR OPPOSITION
Apr 3, 2012 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 14, 2012 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Feb 27, 2012 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 21, 2012 CNSA
EXAMINER'S AMENDMENT ENTERED
Feb 10, 2012 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Feb 10, 2012 GNEN
EXAMINERS AMENDMENT E-MAILED
Feb 10, 2012 GNEA
EXAMINERS AMENDMENT -WRITTEN
Feb 10, 2012 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 1, 2012 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 1, 2012 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 10, 2012 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jul 12, 2011 GNRN
NON-FINAL ACTION E-MAILED
Jul 12, 2011 GNRT
NON-FINAL ACTION WRITTEN
Jul 12, 2011 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 21, 2011 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 21, 2011 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 15, 2011 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Dec 21, 2010 GNRN
NON-FINAL ACTION E-MAILED
Dec 21, 2010 GNRT
NON-FINAL ACTION WRITTEN
Dec 21, 2010 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 30, 2010 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 30, 2010 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 29, 2010 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 27, 2010 GNRN
NON-FINAL ACTION E-MAILED
May 27, 2010 GNRT
NON-FINAL ACTION WRITTEN
May 27, 2010 CNRT
ASSIGNED TO EXAMINER
May 20, 2010 DOCK
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
Apr 9, 2010 AMPX
ASSIGNED TO LIE
Apr 8, 2010 ALIE
TEAS VOLUNTARY AMENDMENT RECEIVED
Mar 29, 2010 PARI
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 23, 2010 NWOS
NEW APPLICATION ENTERED
Feb 20, 2010 NWAP